| Helicobacter pylori infection influences nocturnal gastric acid breakthrough. | |
| | |
MedLine Citation:
|
PMID: 10930899 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Nocturnal gastric acid breakthrough is defined as night-time periods when gastrin pH falls below 4.0 for greater than 1h during administration of a proton pump inhibitor. This phenomenon is a serious problem for patients who require strict control of their gastric acid secretions. AIM: To investigate the prevalence of nocturnal gastric acid breakthrough in Japanese subjects during administration of rabeprazole, and to clarify the relationship between Helicobacter pylori infection and nocturnal gastric acid breakthrough. METHODS: Thirty-one normal male volunteers were examined by ambulatory 24 h gastric pH monitoring four times: without medication, after a morning or an evening dose of 20 mg rabeprazole, and after administration of an H2-receptor antagonist at bedtime, in addition to the morning dose of rabeprazole. H. pylori infection was determined by the 13C-urea breath test and an assay for serum anti-H. pylori antibody. RESULT: Nocturnal gastric acid breakthrough was observed in 12 patients (39%) after the morning dose of 20 mg rabeprazole. In all cases, nocturnal gastric acid breakthrough was inhibited completely by administration of the H2-receptor antagonist at bedtime. Only one patient with nocturnal gastric acid breakthrough had H. pylori infection. CONCLUSION: The absence of H. pylori infection appears to be closely related to the occurrence of nocturnal gastric acid breakthrough during dosing with a proton pump inhibitor. |
| | |
Authors:
|
T Katsube; K Adachi; A Kawamura; K Amano; Y Uchida; M Watanabe; Y Kinoshita |
Related Documents
:
|
3410049 - Importance of sulfhydryl group for rabbit gastric lipase activity. 5015049 - Gastric stasis and gastric ulcer after selective vagotomy without a drainage procedure. 12235069 - Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibio... 6750829 - Prostaglandin and protection of the gastroduodenal mucosa. 4032859 - Gastric antral ulcers induced by a combination of acid, indomethacin and ischemia in rats. 21829 - Estimation of serum acid proteases at ph 1.8 and ph 3.5 in patients with duodenal ulcer... 17897199 - Partitioning of ochratoxin a in mycelium and conidia of aspergillus carbonarius and the... 16631439 - Maternal folic acid supplementation to dams on marginal protein level alters brain fatt... 2898959 - Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 14 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2000 Aug |
Date Detail:
|
Created Date: 2000-10-10 Completed Date: 2000-10-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 1049-56 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine II, Shimane Medical University, Izumo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Adult Anti-Ulcer Agents / pharmacology Benzimidazoles / pharmacology Circadian Rhythm Gastric Acid / metabolism* Gastric Acidity Determination Helicobacter Infections / metabolism* Helicobacter pylori* Humans Hydrogen-Ion Concentration Male Middle Aged Omeprazole / analogs & derivatives |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 117976-90-6/rabeprazole; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical ...
Next Document: Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral a...